FDA Decision Memorandum on Semaglutide Shortage Resolution – February 21, 2025

FDA Decision Memorandum on Semaglutide Shortage Resolution – February 21, 2025

Regular price $69.00 USD
Regular price Sale price $69.00 USD
Sale Sold out
Original Request: Please provide us with the redacted version of FDA's February 21, 2025 decision memorandum regarding the decision to designate the shortage of Novo Nordisk’s Semaglutide drug as resolved.
Tags: Pharma, Recall, 2025
  • Status: Pending Fast-Track Request
  • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. IMPORTANT: The FDA FOIA office operations are currently suspended. We are happy to make the request but do not know when we will receive a response. Learn more about Fast-Track Requests here.

View full details